Zepzelca, a new drug introduced to Korea by Boryung, can now be prescribed in the Big 5 general hospitals in Korea.

According to industry sources, the small cell lung cancer treatment Zepzelca (lurbinectedin) has passed the drug committees (DCs) of all the top 5 tertiary hospitals in Korea – Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary’s Hospital, Seoul Asan Medical Center, and Sinchon Severance Hospital, and has been listed in 60% of all medical institutions nationwide that offer lung cancer treatment services.

The only issue that remains is that Zepzelca is yet to be reimbursed. The company is preparing to submit an application for its reimbursemen